[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336671-105":59,"doc-detail-336671-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","non-small-cell-lung-cancer-patients-harboring-ros1-rearrangement-real-world-testing-practices-characteristics-and-treatment-patterns-ros1real-study","Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement - Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)","","ROS1 rearrangements are uncommon in non-small-cell lung cancer (NSCLC). This retrospective multi-center real-world study evaluated first-line therapy patterns using crizotinib, the standard-of-care tyrosine kinase inhibitor, versus next-generation ROS1 agents. The cohort included 49 patients with advanced metastatic disease, with molecular profiling performed by FISH/CISH or NGS. Outcomes compared overall response, disease control, progression-free survival, and central nervous system progression between treatment groups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/non-small-cell-lung-cancer-patients-harboring-ros1-rearrangement-real-world-testing-practices-characteristics-and-treatment-patterns-ros1real-study/336671/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/non-small-cell-lung-cancer-patients-harboring-ros1-rearrangement-real-world-testing-practices-characteristics-and-treatment-patterns-ros1real-study/336671.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the ROS1REAL study?","Question",{"text":112,"@type":113},"To evaluate first-line treatment with crizotinib versus next-generation ROS1 anti-cancer agents in a real-world setting for NSCLC patients harboring ROS1 rearrangements.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients grouped and what treatments were compared?",{"text":117,"@type":113},"Forty-nine advanced metastatic NSCLC patients were included; 28 received crizotinib, 14 received newer ROS1 agents (entrectinib or repotrectinib), and 7 received platinum-doublet chemotherapy as first-line therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How were ROS1 rearrangements detected in this study?",{"text":121,"@type":113},"Molecular profiling used tissue samples analyzed by FISH/CISH or NGS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336671,1791181815,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nNon-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)  \nUrska Janzic 1,2,†, Natalie Maimon Rabinovich 3,†, Walid Shalata 4, Waleed Kian 5, Katarzyna Szymczak 6, Rafal Dziadziuszko 6, Marko Jakopovic 7, Giannis Mountzios 8,†, Adam Pluzanski 9, Antonio Araujo 10, Andriani Charpidou 11, Sameh Daher 12 and Abed Agbarya 13,14, *  \nCitation: Janzic, U.; Maimon Rabinovich, N.; Shalata, W.; Kian, W.; Szymczak, K.; Dziadziuszko, R.; Jakopovic, M.; Mountzios, G.;  \nPluzanski, A.; Araujo, A.; et al.  \nNon-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study) . Curr. Oncol. 2024, 31, 4369–4381. [https://](https://)[ ](https://)[doi.org/10.3390/curroncol31080326](doi.org/10.3390/curroncol31080326)  \nReceived: 3 July 2024  \nRevised: 25 July 2024  \nAccepted: 26 July 2024  \nPublished: 30 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia; [urska.janzic@klinika-golnik.sl](urska.janzic@klinika-golnik.sl)  \n2 Medical Faculty Ljubliana, University of Ljubliana, 1000 Ljubljana, Slovenia  \n3 Lung Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba 4428163, Israel; [natalie.maimon@clalit.org.il](natalie.maimon@clalit.org.il)  \n[4](4 The Legacy Heritage Cancer Center & Dr)[ The Legacy Heritage Cancer Center & Dr](4 The Legacy Heritage Cancer Center & Dr). Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel; [walid_sh@clalit.org.il](walid_sh@clalit.org.il)  \n5 Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem 9436008, Israel; [waleedkian77@gmail.com](waleedkian77@gmail.com)  \n6 Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, University of Gda ´nsk, 80-210 Gda ´nsk, Poland; [kszymczak@uck.gda.pl](kszymczak@uck.gda.pl) (K.S.); [rafald@gumed.edu.pl](rafald@gumed.edu.pl) (R.D.)  \n7 Department of Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia; [marko.jakopovic@kbc-zagreb.hr](marko.jakopovic@kbc-zagreb.hr)  \n8 Clinical Trials Unit, Fourth Oncology Department, Henry Dunant Hospital Center, 115 26 Athens, Greece; [gmountzios@gmail.com](gmountzios@gmail.com)  \n9 Department of Lung Cancer and Chest Tumors, The Maria Sklodowska-Curie National Research Institute of Oncology, 00-001 Warsaw, Poland  \n10 Department of Medical Oncology, ULS de Santo António, 4099-001 Porto, Portugal; [antonio.araujo@chporto.min-saude.pt](antonio.araujo@chporto.min-saude.pt)  \n11 Oncology Unit, 3rd Department of Medicine,“Sotiria” Hospital for Diseases of the Chest, National and Kapodistrian University of Athens, 106 79 Athens, Greece; [dcharpidou@yahoo.com](dcharpidou@yahoo.com)  \n12 Thoracic Cancer Unit, Cancer Division, Rambam Health Care Campus, Haifa 3525408, Israel; [s_daher@rambam.health.gov.il](s_daher@rambam.health.gov.il)  \n13 Department of Oncology, Bnai-Zion Medical Center, 47 Golomb Avenue, Haifa 31048, Israel  \n14 Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Haifa 31096, Israel  \n* Correspondence: [abed.agbarya@b-zion.org.il](abed.agbarya@b-zion.org.il); Tel.: +972-4-8359016 † These authors contributed equally to this work.  \nAbstract: ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC) . This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor","cbCaifMIGRTKl12b","https://ap.wps.com/l/cbCaifMIGRTKl12b","pdf",634565,13,"English","# Introduction\n# Abstract\n## Study Design and Objectives\n## Treatment Groups and Outcomes\n## Molecular Profiling Methods","[{\"question\":\"What was the main goal of the ROS1REAL study?\",\"answer\":\"To evaluate first-line treatment with crizotinib versus next-generation ROS1 anti-cancer agents in a real-world setting for NSCLC patients harboring ROS1 rearrangements.\"},{\"question\":\"How were patients grouped and what treatments were compared?\",\"answer\":\"Forty-nine advanced metastatic NSCLC patients were included; 28 received crizotinib, 14 received newer ROS1 agents (entrectinib or repotrectinib), and 7 received platinum-doublet chemotherapy as first-line therapy.\"},{\"question\":\"How were ROS1 rearrangements detected in this study?\",\"answer\":\"Molecular profiling used tissue samples analyzed by FISH/CISH or NGS.\"}]","Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement - Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study) | PDF",1790016117,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e08c62a129019d45d596e7c14117b37.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcaeaff8ad83e7c93824410c9e4b61c2.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e72ebec7b43200c6e0b62581f7d44b3d.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cec3413169c7bb72adb687cd92993918.webp",980,1385]